Dr. Isabelle Lechat

Active

Private limited companyfounded 2017active for 8 yearsSorbrechtshofstraat 19, 2650 Edegem, BelgiumKBO/BCE: BE 0684.859.392

From the official registers: KBO 8 annual accounts at the National Bank publications in the Belgian Official Gazette

Summary

Dr. Isabelle Lechat has been active since 2017 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €82,468 and a net result of €9,719. Equity fluctuates too strongly from year to year to read a trend from it. Its solvency ranks better than 76% of 20,678 sector peers (NACE 86, financial year 2025). The computed 12-month bankruptcy probability is below 0.1% (very low).

Risk analysisFollow Report Compare

Dr. Isabelle LechatActiveChecked score 94/100

Risk analysis Report Compare

Official details

KBO

Status: Active since 21-11-2017 Normal situation
Legal form: Private limited company
Registered office: Sorbrechtshofstraat 19, 2650 Edegem
Activity: General medical practice NACE 86210and 1 other
Establishment unit: 2.270.216.209 2650 Edegem, since 01-01-2018
Financial year end: 31 December
Peppol: Reachable since 09-10-2024

Company details

Board and ownership

Board

LECHAT,Isabelle Monica Alberte Agnes Claude GhislainDirector · since 07-11-2017

Board & ownership

Financial position

94 Excellent Checked score 2025

Bankruptcy probabilitywithin 12 months: < 0.1%

Annual accounts 2025

Gross margin: €19,740; ▼ 88.2%
Turnover: ≈ €130,000; estimated
Profit: €9,719; ▼ 92.0%
Equity: €82,468; ▼ 42.0%
Total assets: €97,809; ▼ 47.8%

2025 accounts filed 39 days before the deadline

Filed on 22-06-2026at the National Bank

Financials

Score breakdownraises risk1 change of registered office in 24 monthslowers riskLiquidity: current ratio 5.56, cash €61,629, halvedSector: Human health activities (NACE 86)Equity €82,468 (84.3% of total assets)Show the evidence

Checked score

Score 2025

94 / 100

Excellent

Probability in this band: under 0.55%

Financially stronger than 52% of micro companies in human health (NACE 86)

Every signal that counts is listed under Signals.

Financial strength · tick: 2024

Strong

Solvency 100=

equity 84.3% of total assets

Liquidity 96+5

short-term debt 15.7% · cash 63.0%

Profitability 81-19

return on assets 9.9%

Bankruptcy probability within 12 months

< 0.1% Very low

0%0.5%1.5%4%10%≥ 25%

Fewer than 1 in 1,000 comparable companies go bankrupt within 12 months (an estimate).

Sector median < 0.1% (24,155 companies, NACE 86, micro)

Last 24 months 11-2024: < 0.1% 12-2024: < 0.1%● unchanged vs 11-2024 01-2025: < 0.1%● unchanged vs 12-2024 02-2025: < 0.1%● unchanged vs 01-2025 03-2025: < 0.1%● unchanged vs 02-2025 04-2025: < 0.1%● unchanged vs 03-2025 05-2025: < 0.1%● unchanged vs 04-2025 06-2025: < 0.1%● unchanged vs 05-2025 07-2025: < 0.1%● unchanged vs 06-2025 08-2025: < 0.1%● unchanged vs 07-2025 09-2025: < 0.1%● unchanged vs 08-2025 10-2025: < 0.1%● unchanged vs 09-2025 11-2025: < 0.1%● unchanged vs 10-2025 12-2025: < 0.1%● unchanged vs 11-2025 01-2026: < 0.1%● unchanged vs 12-2025 02-2026: < 0.1%● unchanged vs 01-2026lowest value 03-2026: < 0.1%● unchanged vs 02-2026 04-2026: < 0.1%● unchanged vs 03-2026 05-2026: < 0.1%● unchanged vs 04-2026 06-2026: < 0.1%● unchanged vs 05-2026 07-2026: < 0.1%● unchanged vs 06-2026 08-2026: < 0.1%● unchanged vs 07-2026 09-2026: 0.1%▲ +0.1 percentage points vs 08-2026highest value 10-2026: < 0.1%▼ -0.1 percentage points vs 09-2026

Credit of up to €7,000 on 30-day terms is acceptable

Liquidity is ample, with a current ratio of 5.56 (3.93 in 2024), above the usual 1.5. Short-term debt is 15.7% and cash 63% of total assets. 15.7% of the assets are financed with debt and provisions.

Calculation

The band follows from the bankruptcy probability. 10 more points roughly halve it.

75-100	Excellent	under 0.55%
60-74	Healthy	0.55% to 1.5%
45-59	Fair	1.5% to 4.2%
25-44	Weak	4.2% to 15.0%
0-24	Critical	over 15.0%

Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 86, micro). It does better than 82% of them on solvency, 85% on liquidity, 28% on profitability and 14% on growth.

The bankruptcy probability was computed on 31-10-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.

Some facts cap the score, however low the probability. With negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late, the score is Fair at most (59). With two missing filings, it is Weak at most (44). During a judicial reorganisation or at the company's end (bankruptcy, dissolution, liquidation), it is Critical at most (24).

Credit check for an amount and term of your choice

Show the recommended maximum and see how the verdict changes with amount, term and advance.

Signals

Five signals.

lowers riskraises riskneutral

Liquidity: current ratio 5.56, cash €61,629, halved

NBB · annual accounts

Sector: Human health activities (NACE 86)

KBO

1 change of registered office in 24 months

Belgian Official Gazette

Equity €82,468 (84.3% of total assets)

NBB · annual accounts

Latest accounts filed on time

The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 22-06-2026, 39 days ahead of the deadline.

NBB · 8 filings

Deviation from the deadline

2025

39 days early

2024

22 days early

2023

5 days early

2022

5 days early

2021

18 days early

2020

16 days early

2019

14 days early

← before the deadline after the deadline →

tick = median of all Belgian filingsring = median in the sector

The company filed its last 7 accounts on average 17 days before the deadline. In the sector (NACE 86), the median for financial year 2024 was 7 days before the deadline, and 36% of those companies filed late.

Searched, nothing found (2)

Next filing not due yet

The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. The company usually files around 13 July (5 of the last 5 filed years within 30 days of that day).

Companies Code · seven months

Where today falls in the filing period

01-11-2026 today31-12-2026 year end31-07-2027 deadline

No strike-offs in the KBO publications

That holds for every publication since 2021.

KBO publications

Key points

Caution: Result fell in 2025from €121,935 to €9,719 ▼ 92.0% View
Caution: Lower net result than 83% of companies in human healthsector median €60,139 · 20,665 companies €9,719 View
Positive: Always filed on timeaccounts within the deadline every year 8 years View
Positive: 8 profitable years in a rowprofit 2025: €9,719 8 years View

Documents

Key facts about Dr. Isabelle Lechat

What is the company number of Dr. Isabelle Lechat?: The company number of Dr. Isabelle Lechat is 0684.859.392. The VAT number is the same number with BE in front: BE 0684.859.392.
Where is Dr. Isabelle Lechat based?: The registered office is at Sorbrechtshofstraat 19, 2650 Edegem.Company details
What does Dr. Isabelle Lechat do?: According to the KBO register, the main activity is general medical practice (NACE 86210).
What is the legal form of Dr. Isabelle Lechat?: The legal form of Dr. Isabelle Lechat is Private limited company (BV).
When was Dr. Isabelle Lechat founded?: Dr. Isabelle Lechat was founded on 21-11-2017.
Is Dr. Isabelle Lechat still active?: Yes, Dr. Isabelle Lechat is an active enterprise in the KBO register.
What is the turnover of Dr. Isabelle Lechat?: The turnover in financial year 2025 is ≈ €130,000. This figure is estimated from the gross margin of €19,740 and 48 comparable companies (NACE 86). It probably lies between €89,000 and €210,000. It is a rough estimate.Financials
Is Dr. Isabelle Lechat profitable?: In financial year 2025, Dr. Isabelle Lechat made a profit of €9,719.
Where can I find the annual accounts of Dr. Isabelle Lechat?: Dr. Isabelle Lechat filed 8 annual accounts with the National Bank of Belgium, the latest for financial year 2025.Annual accounts at the National Bank
When are the next annual accounts of Dr. Isabelle Lechat due?: Dr. Isabelle Lechat must file the annual accounts for financial year 2026 by 31-07-2027.Timeline

Comparable companies

These companies have the same main activity as Dr. Isabelle Lechat: general medical practice (NACE 86210). They are comparable in size and age: total assets between €98,900 and €135,000, founded between 2015 and 2019.

Company	Total assets	Gross margin
Dr. Isabelle Lechat Edegem	€97,809	€19,740
Dr. Demaeght Guy Geel	€101,828	€20,030
Huisartsen De Komme Brugge	€120,677	€18,488
Esculape Médicus Rixensart	€98,877	€23,652
HUISARTS EMMA DUJARDIN Gent	€112,658	€22,137
Bart DONDERS huisarts Overijse	€116,470	€23,559
Dr. Evelien Byloos Haacht	€134,641	€18,039